Radius Health, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Radius Health, Inc.
CEO sees Guardant360 CDx approval as "watershed moment" for liquid biopsy and plans more biopharma partnerships.
The liquid-biopsy test is also a companion diagnostic for osimertinib, AstraZeneca’s drug for non-small cell lung cancer.
While COVID-19 testing capacity rises slowly the in UK, the scientific community is pressing to develop the range of test types to get the numbers up further to secure sustainable control of the disease.
The COVID-19 antibody tests that so far have gone through the validation process have not proven accurate enough to be rolled out for public use, says the UK. A new rapid test consortium is working on a solution.
- Specialty Pharmaceuticals
- Large Molecule
- Other Names / Subsidiaries
- NuVios, Inc.